October 2026—In the never-ending search for new cancer biomarkers, there is always at least one new hopeful waiting in the wings, readying for a potential elevation (so to speak) to star status. Among the latest to generate buzz (at least in the form of oncologists asking about testing) are MTAP deletions. Could these be the latest to have a breakout role? There are many good reasons to think so, says Eric Vail, MD.
October 2026—Antibiotic resistance has changed dramatically. How laboratories detect antibiotic resistant infections and how patients are treated have not. “We treat patients with our best-guess drugs, and we make those guesses based on the types of infections we’re seeing in the patients we take care of and what our local antibiotic resistance rates look like,” says Romney Humphries, PhD, D(ABMM), M(ASCP).
This conversation is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with representatives of a company to spotlight its laboratory solutions. He spoke on July 21 with Nick Fingland, PhD, PMP, senior director of R&D operations and science, BD, and Chris Farnsworth, PhD, D(ABCC), section head of clinical chemistry.
October 2026—We have all heard the latest claims that the American Medical Association—and the medical specialties it represents—is misusing CPT codes to overpay physicians. Whether these statements come from the Medicare Payment Advisory Commission, members of Congress, or any other group, it’s no wonder we pathologists feel under attack.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Hematology Analyzers
October 2026—Differential reviews, reference ranges, longitudinal data, AI, and information silos were front and center when CAP TODAY publisher Bob McGonnagle led a discussion online in early September about hematology analyzers and the needs of laboratories and clinicians.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
June 2022—Siemens Healthineers announced the FDA has granted breakthrough device designation for the Advia Centaur serum neurofilament light chain (sNfL) assay, developed in collaboration with Novartis Pharma. The assay quantitatively measures NfL in human serum and plasma and is intended to be used in conjunction with clinical, imaging, and laboratory findings as an aid in identifying adult patients with relapsing multiple sclerosis who are at lower risk, versus higher risk, of multiple sclerosis disease activity.